ATE55908T1 - Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms. - Google Patents

Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.

Info

Publication number
ATE55908T1
ATE55908T1 AT84301513T AT84301513T ATE55908T1 AT E55908 T1 ATE55908 T1 AT E55908T1 AT 84301513 T AT84301513 T AT 84301513T AT 84301513 T AT84301513 T AT 84301513T AT E55908 T1 ATE55908 T1 AT E55908T1
Authority
AT
Austria
Prior art keywords
respiratory distress
distress syndrome
treatment
active agent
surfactant
Prior art date
Application number
AT84301513T
Other languages
English (en)
Inventor
Takei Tsunetomo
Kanazawa Yosaku
Masuda Kazuo
Tanaka Yuji
Original Assignee
Tokyo Tanabe Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12518415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE55908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tokyo Tanabe Co filed Critical Tokyo Tanabe Co
Application granted granted Critical
Publication of ATE55908T1 publication Critical patent/ATE55908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AT84301513T 1983-03-10 1984-03-07 Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms. ATE55908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP58038189A JPS59164724A (ja) 1983-03-10 1983-03-10 サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
EP84301513A EP0119056B1 (de) 1983-03-10 1984-03-07 Grenzflächenaktives Mittel und dieses enthaltende Arzneimittel zur Verwendung bei der Behandlung des Atemnotsyndroms

Publications (1)

Publication Number Publication Date
ATE55908T1 true ATE55908T1 (de) 1990-09-15

Family

ID=12518415

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84301513T ATE55908T1 (de) 1983-03-10 1984-03-07 Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.

Country Status (10)

Country Link
US (1) US4603124A (de)
EP (1) EP0119056B1 (de)
JP (1) JPS59164724A (de)
AT (1) ATE55908T1 (de)
AU (1) AU562676B2 (de)
CA (1) CA1208129A (de)
DE (1) DE3483055D1 (de)
GR (1) GR81930B (de)
IE (1) IE57006B1 (de)
MX (1) MX9203493A (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430020A (en) * 1984-12-11 1995-07-04 Scios Nova Inc. Recombinant alveolar surfactant protein
US5110806A (en) * 1985-06-26 1992-05-05 The Regents Of The University Of California Lung surfactant compositions
DE3528934A1 (de) * 1985-08-13 1987-02-26 Feldmuehle Ag Gleitelement aus keramischem werkstoff
WO1987002037A1 (en) * 1985-09-26 1987-04-09 Genetics Institute, Inc. Pulmonary surfactant proteins
US5256569A (en) * 1986-01-21 1993-10-26 Chisso Corporation Transesterification process for otereoselection of enantiomers of secondary alcohols using pseudomonas lipase with no added solvent
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
DE3921954A1 (de) * 1989-07-04 1991-01-17 Thomae Gmbh Dr K Niedrig-viskose, hochkonzentrierte surfactant-suspension
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5207220A (en) * 1989-12-12 1993-05-04 Burroughs Wellcome Co. Method for administering pharmaceuticals, including liquid surfactant, to the lungs
FR2658418B1 (fr) * 1990-02-20 1994-09-02 Synthelabo Compositions pharmaceutiques a base de phospholipides.
CA2083171C (en) * 1990-05-18 2002-09-10 Kurashima Kazuyoshi Antasthmatic
US5614216A (en) * 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
JP3961029B2 (ja) * 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
BR9506114A (pt) * 1994-12-29 1997-12-23 Ctro Nac Sanidad Agropecuaria Tensoativo pulmonar de origem suína e processo para a sua obtenção
US6129934A (en) * 1995-06-07 2000-10-10 Ony, Inc. Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
WO1997026863A1 (de) 1996-01-24 1997-07-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen
US6172203B1 (en) * 1996-02-07 2001-01-09 Alfredo Adolfo Hager Method for extracting and purifying pulmonary surfactant
AU2322097A (en) * 1996-03-27 1997-10-17 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US5667948A (en) * 1996-04-16 1997-09-16 Eastman Kodak Company Processing silver halide films with an aqueous phospholipid rinse solution
US6395295B1 (en) 1997-12-24 2002-05-28 Britannia Pharmaceuticals Limited Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE10018022A1 (de) * 2000-04-12 2001-10-31 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
GB0026239D0 (en) * 2000-10-26 2000-12-13 Britannia Pharmaceuticals Ltd Surface active lipids in treatment of wet lung
WO2003006989A1 (fr) * 2001-07-12 2003-01-23 Kyowa Medex Co., Ltd. Procede de quantification de lipoproteines denaturees, reactifs pour la quantification de lipoproteines denaturees, procede de detection de maladies du systeme circulatoire et reactifs pour la detection de maladies du systeme circulatoire
EP1435994B1 (de) 2001-10-11 2010-05-19 Nycomed GmbH Neue verwendung von lungensurfactant
EP1481665A1 (de) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Neue Lipidmischungen für synthetische Tenside
ATE457736T1 (de) 2004-08-06 2010-03-15 Nycomed Gmbh Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
WO2010068754A2 (en) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
CN103052380B (zh) 2010-08-23 2015-11-25 塔科达有限责任公司 包含治疗活性物质的湿润颗粒
IN2014DN08538A (de) * 2012-03-28 2015-05-15 Discovery Lab Inc

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE388023C (de) * 1922-02-14 1924-01-07 Chem Fab Verfahren zur Herstellung von waesserigen Lezithinemulsionen
FR2343481A1 (fr) * 1976-03-11 1977-10-07 Gerlich Norbert Composition destinee a empecher les lesions des membranes biologiques et a regenerer ces membranes une fois qu'elles ont ete endommagees
DE2900300A1 (de) * 1979-01-05 1980-07-17 Lebrecht Von Dr Klitzing Verfahren einer prophylaxe zur vermeidung des atemnotsyndroms bei fruehgeborenen und bei der schocklunge
JPS55160721A (en) * 1979-06-02 1980-12-13 Tokyo Tanabe Co Ltd Pulmonary surfactant ta-546, its preparation, and remedy for pulmonary hyaline membrane syndrome comprising it as active constituent
US4312860A (en) * 1980-10-24 1982-01-26 Regents Of The University Of California Lung surfactant compositions
JPS5845299A (ja) * 1981-09-10 1983-03-16 東京田辺製薬株式会社 新規な表面活性物質、その製造法及びそれを含有する呼吸窮迫疾候群治療剤

Also Published As

Publication number Publication date
JPH0378371B2 (de) 1991-12-13
EP0119056A2 (de) 1984-09-19
IE57006B1 (en) 1992-03-11
IE840553L (en) 1984-09-10
CA1208129A (en) 1986-07-22
US4603124A (en) 1986-07-29
MX9203493A (es) 1992-08-01
GR81930B (de) 1984-12-12
AU562676B2 (en) 1987-06-18
JPS59164724A (ja) 1984-09-17
AU2512584A (en) 1984-09-13
EP0119056B1 (de) 1990-08-29
DE3483055D1 (de) 1990-10-04
EP0119056A3 (en) 1986-06-25

Similar Documents

Publication Publication Date Title
ATE55908T1 (de) Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.
Heppleston et al. Changes in the composition of lung lipids and the “turnover” of dipalmitoyl lecithin in experimental alveolar lipo-proteinosis induced by inhaled quartz
JPS5799524A (en) Mammal lung surface active drug composition
SE8803713D0 (sv) Biologically active lipoprotein and its use
DE10299015I1 (de) Arzneimittel enthaltend Dipyridamol oder Mopidamol und O-Acetylsalicylsaeure bzw deren physiologisch vertraegliche Salze Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekaempfung der Thrombusbildung
DE69324671D1 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
ATE144142T1 (de) Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
NO912943D0 (no) Anvendelse av nervonsyre og langkjedete fettsyrer for behandling av demyelineringsforstyrrelser.
DK0658101T3 (da) Aerosolformuleringer fri for overfladeaktivt middel og indeholdende beclomethasondipropionat
DE3855113D1 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
ATE35415T1 (de) Pharmazeutische zusammensetzungen und verfahren fuer die herstellung von zusammensetzungen mit gehalt an phosphatidylserine zur behandlung von stoerungen des centralen nervensystems ohne wirkungen auf die blutkoagulation.
AR224128A1 (es) Un compuesto derivado de esteres del acido n'-(fenil o tienil-sulfonil)-n-(pirimidin o triazin-2-il)-carbamimidotioico,procedimiento para su preparacion y composicion que lo contiene
ATE43244T1 (de) Pharmazeutische zusammensetzung in form einer salbe zur dermischen und ophthalmischen verwendung.
ATE18549T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
JPS5592312A (en) Suppository containing bronchodilating compound
ATE227304T1 (de) Tetraetherlipide und diese enthaltende liposomen sowie deren verwendung
JPS56127308A (en) Blood-coagulation factor 8 pharmaceutical
ATE183648T1 (de) Arzneimittel enthaltend mischungen von höheren primären aliphatischen alkoholen zur behandlung von hypercholesterolämie und hyperlipoproteinämie typ ii und zur stimulation des sexuellen verhaltens bei tieren und menschen
ES482684A1 (es) Procedimiento de preparacion de nuevos derivados de la pipe-ridilbencimidazolinona y de sus sales de adicion con acidos apropiados.
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
ATE91418T1 (de) Mittel zur behandlung der herzinsuffizienz.
ATE119908T1 (de) 2-formylbenzylphosphonsäure-derivate, deren herstellung und ihre verwendung zur behandlung von durch viren verursachte krankheiten.
NO913685D0 (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
PT70288A (de) Carbanilsaure-/3-(alkylcarbonylamino)-phenyl/-ester verfahren zur herstellung dieser verbindungen sowie diese enthaltendes herbizides mittel
JPS5626819A (en) Preventive for hypoimmunity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked